8-KMaterial AgreementsFinancial EventsExhibits & Filings

AbbVie Inc. 8-K Report, Material Agreement (May 14, 2015)

Filed May 14, 2015For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K on May 14, 2015, to report on the completion of a significant debt offering and the termination of a prior financing agreement. The company successfully issued $16.7 billion in senior notes across various maturities, ranging from 2018 to 2045, with coupon rates from 1.800% to 4.700%. These proceeds are primarily earmarked to fund the cash component of AbbVie's acquisition of Pharmacyclics, Inc., as well as to finance potential share repurchases related to that transaction and cover associated expenses. Crucially, this debt issuance replaces AbbVie's previously established $18.0 billion 364-day bridge term loan facility. The termination of this bridge loan agreement, dated March 27, 2015, indicates a shift in AbbVie's financing strategy for the Pharmacyclics acquisition, moving from a short-term facility to a longer-term, multi-tranche debt structure. Investors should note the special mandatory redemption clause for the new senior notes; if the Pharmacyclics acquisition does not close by February 3, 2016, or is terminated, AbbVie will be obligated to redeem these notes at a premium (101% of principal) plus accrued interest.

Key Highlights

  • 1AbbVie completed a $16.7 billion public offering of senior notes across six tranches with maturities from 2018 to 2045.
  • 2The notes carry fixed interest rates ranging from 1.800% to 4.700%.
  • 3Proceeds from the offering are intended to fund the cash portion of the Pharmacyclics acquisition and related share repurchases.
  • 4AbbVie terminated its $18.0 billion 364-day bridge term loan facility used for the Pharmacyclics acquisition.
  • 5The issuance of these notes effectively replaces the bridge loan as the primary financing for the Pharmacyclics deal.
  • 6A special mandatory redemption provision requires AbbVie to redeem the notes at 101% of principal plus accrued interest if the Pharmacyclics acquisition does not close by February 3, 2016, or if the merger agreement is terminated.

Frequently Asked Questions

The primary purpose of the $16.7 billion senior notes offering is to finance the cash component of AbbVie's acquisition of Pharmacyclics, Inc. It will also be used to fund potential share repurchases related to this acquisition and cover associated transaction fees and expenses. Any remaining proceeds will be used for general corporate purposes.

AbbVie terminated the $18.0 billion 364-day bridge term loan agreement because the company has secured long-term debt financing through the issuance of senior notes. This indicates a strategic decision to replace the short-term bridge financing with a more permanent capital structure to fund the Pharmacyclics acquisition.

If the Pharmacyclics acquisition does not close by February 3, 2016, or if the merger agreement is terminated before closing, AbbVie is required to redeem all of the issued senior notes. The redemption price will be 101% of the principal amount, plus any accrued and unpaid interest up to the redemption date.

The senior notes consist of the following: $3.0 billion of 1.800% notes due 2018, $3.75 billion of 2.500% notes due 2020, $1.0 billion of 3.200% notes due 2022, $3.75 billion of 3.600% notes due 2025, $2.5 billion of 4.500% notes due 2035, and $2.7 billion of 4.700% notes due 2045.